Gradientech expands with senior business development presence in the US

Report this content

The diagnostics company Gradientech today announces the signing of a long-term agreement with Marc van Nuenen for heading the company’s business development activities in the US including preparation for clinical studies towards an FDA approval of the QuickMIC® system.

Marc van Nuenen and Gradientech have agreed on a long-term collaboration to prepare and set up clinical studies and head commercial activities in the US for the rapid antibiotic susceptibility testing system QuickMIC by Gradientech.

“It is my great pleasure to invite Marc to the team. His unparalleled network and his deep knowledge of our business will be pivotal for our future US entry and to Gradientech in general”, says Peter Karlberg, VP Sales at Gradientech.

Marc van Nuenen contributes with over 30 years of commercial experience in the clinical microbiology industry. His earlier assignments include heading the commercial developments in mass spectrometry with the VITEK MS product line at bioMérieux. Following the acquisition of BioFire in 2014 by bioMérieux, Marc was leading the global commercial expansion of the molecular diagnostic system FilmArray, first across Europe and the Middle East, followed by Asia-Pacific in his roles as VP BioFire Commercialisation EMEA, and latest in the same role for APAC.


“It is a true honour to team up with the talented group at Gradientech. Not only is the QuickMIC system the fastest phenotypic AST system on the market today with results available within 2-4 hours, the precise linear MIC results it generates are showing incredible promise to elevate AST to a whole new level of clinical utility”, says Marc van Nuenen.

For further information, please contact:
Sara Thorslund, CEO
Tel: + 46 
763 29 35 80

Marc van Nuenen, VP Business Development US
Tel: +1 (919) 808-7190


About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit for more information.